eurotimes.org
EUROTIMES STORIES

Evolving platform

Colin Kerr

Posted: Tuesday, May 1, 2018

LENSAR has received 510(k) clearance from the US Food and Drug Administration for the LENSAR Laser System with Streamline IV, expanding the platform’s capabilities to include the creation of the corneal pockets and flaps used in ophthalmic procedures treating presbyopia.

“The continued expansion of capabilities with the LENSAR Laser System is the latest demonstration of our commitment to technological innovation,” said Nicholas Curtis, CEO of LENSAR. “It made sense to evolve our platform to support surgeons meeting the increasing patient demand with options for the treatment of presbyopia with corneal inlay devices.”

http://www.lensar.com/


Latest Articles


escrs members advert